Imidazo[2,1-b]thiazole guanylhydrazones as RSK2 inhibitors

European Journal of Medicinal Chemistry

Volumn 46, Issue 9, 2011, Pages 4311-4323

  Andreani, Aldo ^a   Granaiola, Massimiliano ^a   Leoni, Alberto ^a   Locatelli, Alessandra ^a   Morigi, Rita ^a   Rambaldi, Mirella ^a   Varoli, Lucilla ^a   Lannigan, Deborah ^b   Smith, Jeff ^b   Scudiero, Dominic ^c   Kondapaka, Sudhir ^d   Shoemaker, Robert H ^d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF VIRGINIA   (United States)

^c SAIC FREDERICK INC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antitumor activity; Guanylhydrazones; Imidazo 2,1 b thiazole; RSK2

Indexed keywords

AMIDINOHYDRAZONE; GLYCOGEN SYNTHASE KINASE 3; IMIDAZOLE DERIVATIVE; PROTEIN SERINE THREONINE KINASE INHIBITOR; S6 KINASE; THIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY;

CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; HYDRAZONES; MAGNETIC RESONANCE SPECTROSCOPY; RIBOSOMAL PROTEIN S6 KINASES; SPECTROPHOTOMETRY, INFRARED;

EID: 80052958431     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.07.001     Document Type: Article

References (23)

1. Potential Antitumor Agents. 47. For part 46 see the following: A. Andreani, S. Bellini, S. Burnelli, M. Granaiola, A. Leoni, A. Locatelli, R. Morigi, M. Rambaldi, L. Varoli, N. Calonghi, C. Cappadone, M. Zini, C. Stefanelli, L. Masotti, and R.H. Shoemaker Substituted E-3-(3-indolylmethylene)- 1,3-dihydroindol-2-ones with antitumor activity. In depth study of the effect on growth of breast cancer cells J. Med. Chem. 53 2010 5567 5575
2. A. Andreani, S. Burnelli, M. Granaiola, A. Leoni, A. Locatelli, R. Morigi, M. Rambaldi, L. Varoli, N. Calonghi, C. Cappadone, G. Farruggia, M. Zini, C. Stefanelli, L. Masotti, N.S. Radin, and R.H. Shoemaker New antitumor imidazo[2,1-b]thiazole guanylhydrazones and analogues J. Med. Chem. 51 2008 809 816
3. A. Andreani, M. Granaiola, A. Leoni, A. Locatelli, R. Morigi, M. Rambaldi, G. Lenaz, R. Fato, C. Bergamini, and G. Farruggia Potential antitumor agents. 37. Synthesis and antitumor activity of guanylhydrazones from imidazo[2,1-b]thiazoles and from the new heterocyclic system thiazolo[2′,3′:2,3]imidazo[4,5-c]quinoline J. Med. Chem. 48 2005 3085 3089
4. K. Müller, C. Faeh, and F. Diederich Fluorine in pharmaceuticals: looking beyond intuition Science 317 2007 1881 1886
5. A.G. Jobson, J.H. Cardellina 2nd, D. Scudiero, S. Kondapaka, H. Zhang, H. Kim, R. Shoemaker, and Y. Pommier Identification of a bis-guanylhydrazone [4,4′-diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase Mol. Pharmacol. 72 2007 876 884
6. C.E. Poteet-Smith, J.A. Smith, D.A. Lannigan, T.A. Freed, and T.W. Sturgill Generation of constitutively active p90 ribosomal S6 kinase in vivo. Implications for the mitogen-activated protein kinase-activated protein kinase family J. Biol. Chem. 274 1999 22135 22138
7. U. Doehn, C. Hauge, S.R. Frank, C.J. Jensen, K. Duda, J.V. Nielsen, M.S. Cohen, J.V. Johansen, B.R. Winther, L.R. Lund, O. Winther, J. Taunton, S.H. Hansen, and M. Frödin RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells Mol. Cell. 35 2009 511 522
8. J.A. Smith, C.E. Poteet-Smith, Y. Xu, T.M. Errington, S.M. Hecht, and D.A. Lannigan Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation Cancer Res. 65 2005 1027 1034
9. G.P. Sapkota, L. Cummings, F.S. Newell, C. Armstrong, J. Bain, M. Frodin, M. Grauert, M. Hoffmann, G. Schnapp, M. Steegmaier, P. Cohen, and D.R. Alessi BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo Biochem. J. 401 2007 29 38
10. A. Sitte, H. Paul, and G. Hilgetag Reaction of 2,5-diamino-1,3,4- thiadiazole with α-halo ketones Z. Chem. 7 1967 341 342
11. N.P. Buu-Hoi, N.D. Xuong, and T. Thu-Cuc La Réaction des ω-Bromoacétophénones avec l'Amino-2 thiazole et les Amino-2 benzothiazoles Bull. Soc. Chim. Fr. 1966 1277 1279
12. A. Andreani, M. Granaiola, A. Leoni, A. Locatelli, R. Morigi, M. Rambaldi, M. Recanatini, G. Lenaz, R. Fato, and C. Bergamini Effects of new ubiquinone-imidazo[2,1-b]thiazoles on mitochondrial complex I (NADH-ubiquinone reductase) and on mitochondrial permeability transition pore Bioorg. Med. Chem. 12 2004 5525 5532
13. A. Andreani, M. Rambaldi, and A. Locatelli Herbicidal activity of 5-haloimidazo[2,1-b]thiazoles Collect. Czech. Chem. Comm. 56 1991 2436 2447
14. A. Andreani, A. Leoni, A. Locatelli, R. Morigi, M. Rambaldi, M. Recanatini, and V. Garaliene Potential antitumor agents. 29. Synthesis and potential coanthracyclinic activity of imidazo[2,1-b]thiazole guanylhydrazones Bioorg. Med. Chem. 8 2000 2359 2366
15. A. Andreani, M. Granaiola, A. Leoni, A. Locatelli, R. Morigi, M. Rambaldi, G. Giorgi, and V. Garaliene Potential antitumor agents. 34. Synthesis and antitumor activity of guanylhydrazones from imidazo[2,1-b]thiazoles and from diimidazo[1,2-a:1,2-c]pyrimidine Anticancer Res. 24 2004 203 212
16. T.L. Nguyen, R. Gussio, J.A. Smith, D.A. Lannigan, S.M. Hecht, D.A. Scudiero, R.H. Shoemaker, and D.W. Zaharevitz Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore Bioorg. Med. Chem. 14 2006 6097 6105
17. A. Andreani, S. Burnelli, M. Granaiola, A. Leoni, A. Locatelli, R. Morigi, M. Rambaldi, L. Varoli, G. Farruggia, C. Stefanelli, L. Masotti, and M.W. Kunkel Synthesis and antitumor activity of guanylhydrazones from 6-(2,4-dichloro-5-nitrophenyl)- and 6-pyridyl-imidazo[2,1-b]thiazoles J. Med. Chem. 49 2006 7897 7901
18. A. Andreani, M. Rambaldi, A. Leoni, A. Locatelli, R. Bossa, A. Fraccari, I. Galatulas, and G. Salvatore Potential antitumor agents. 24. Synthesis and pharmacological behavior of imidazo[2,1-b]thiazole guanylhydrazones bearing at least one chlorine J. Med. Chem. 39 1996 2852 2855
19. J.A. Smith, D.J. Maloney, S.M. Hecht, and D.A. Lannigan structural basis for the activity of the RSK-specific inhibitor, SL0101 Bioorg. Med. Chem. 15 2007 5018 5034
20. I.A. Leighton, K.N. Dalby, F.B. Caudwell, P.T. Cohen, and P. Cohen Comparison of the specificities of p70 s6 kinase and MAPKAP kinase-1 identifies a relatively specific substrate for p70 s6 kinase: the N-terminal kinase domain of MAPKAP kinase-1 is essential for peptide phosphorylation FEBS Lett. 375 1995 289 293
21. T.S.K. Eisinger-Mathasona, J. Andrade, and D.A. Lannigan RSK in tumorigenesis: connections to steroid signalling Steroids 75 2010 191 202
22. A.G. Jobson, G.T. Lountos, P.L. Lorenzi, J. Llamas, J. Connelly, D. Cerna, J.E. Tropea, A. Onda, G. Zoppoli, S. Kondapaka, G. Zhang, N.J. Caplen, J.H. Cardellina II, S.S. Yoo, A. Monks, C. Self, D.S. Waugh, R.H. Shoemaker, and Y. Yves Pommier Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-Nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}- amide] J. Pharmacol. Exp. Ther. 331 2009 816 826
23. A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paull, D. Vistica, C. Hose, J. Langley, P. Cronise, A. Vaigro-Wolff, M. Gray-Goodrich, H. Campbell, J. Mayo, and M. Boyd Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines J. Natl. Cancer Inst. 83 1991 757 766